Cumberland Pharmaceuticals Inc.

CPIX Healthcare Drug Manufacturers Specialty & Generic

Cumberland Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, up 17.6% from fiscal 2024.

Revenue
−98.5%
EPS
−480.0%
Free cash flow
−82.8%
Total debt
0.00%

Quarter to June 2026, against a year earlier

5.19 0.18 +3.59%
Market cap
$75.1M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
0.00%
F-score
6/9
Altman Z
0.65
Beneish M
−2.58
Dividend safety
n/a

Cumberland Pharmaceuticals Inc. (CPIX) P/E ratio

Alert me on P/E ratio

Cumberland Pharmaceuticals Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 5,556× (September 2016) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
42 more quarters

Against its own ten years

Low 0.0× High 5,556×
Ten-year median 0.0×
Current reading's percentile 85

P/E ratio against peers

Company P/E ratio
CPIX Cumberland Pharmaceuticals Inc. n/m
SCYX SCYNEXIS, Inc. compare n/m
CTOR Citius Oncology, Inc. compare n/m
TLPH Talphera, Inc. compare n/m
ORGO Organogenesis compare n/m
CRDL Cardiol Therapeutics Inc. compare n/m
INCR InterCure Ltd. compare 6.2×
BGM BGM Group Ltd. compare 148×
ZYBT Zhengye Biotechnology Holding Limited compare —
Drug Manufacturers Specialty & Generic industry median 20.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on CPIX